Abstract

Numerous challenges have impeded HIV-1 vaccine development. Among these is the lack of a convenient small animal model in which to study antibody elicitation and efficacy. We describe a chimeric Rhabdo-Immunodeficiency virus (RhIV) murine model that recapitulates key features of HIV-1 entry, tropism and antibody sensitivity. RhIVs are based on vesicular stomatitis viruses (VSV), but viral entry is mediated by HIV-1 Env proteins from diverse HIV-1 strains. RhIV infection of transgenic mice expressing human CD4 and CCR5, exclusively on mouse CD4+ cells, at levels mimicking those on human CD4+ T-cells, resulted in acute, resolving viremia and CD4+ T-cell depletion. RhIV infection elicited protective immunity, and antibodies to HIV-1 Env that were primarily non-neutralizing and had modest protective efficacy following passive transfer. The RhIV model enables the convenient in vivo study of HIV-1 Env-receptor interactions, antiviral activity of antibodies and humoral responses against HIV-1 Env, in a genetically manipulatable host.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files

Article and author information

Author details

  1. Rachel A Liberatore

    Laboratory of Retrovirology, The Rockefeller University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Emily J Mastrocola

    Laboratory of Retrovirology, The Rockefeller University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Elena Cassella

    Laboratory of Retrovirology, The Rockefeller University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Fabian Schmidt

    Laboratory of Retrovirology, The Rockefeller University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Jessie R Willen

    Laboratory of Retrovirology, The Rockefeller University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Dennis Voronin

    Laboratory of Retrovirology, The Rockefeller University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Trinity M Zang

    Laboratory of Retrovirology, The Rockefeller University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Theodora Hatziioannou

    Laboratory of Retrovirology, The Rockefeller University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Paul D Bieniasz

    Laboratory of Retrovirology, The Rockefeller University, New York, United States
    For correspondence
    pbieniasz@rockefeller.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2368-3719

Funding

National Institute of Allergy and Infectious Diseases (R37AI064003)

  • Paul D Bieniasz

National Institute of Allergy and Infectious Diseases (R01AI078788)

  • Theodora Hatziioannou

National Institute of Allergy and Infectious Diseases (R01AI50111)

  • Paul D Bieniasz

Howard Hughes Medical Institute

  • Paul D Bieniasz

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocol (18047-H) of the Rockefeller University. All surgery was performed under anesthesia, and every effort was made to minimize suffering.

Copyright

© 2019, Liberatore et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,534
    views
  • 218
    downloads
  • 6
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Rachel A Liberatore
  2. Emily J Mastrocola
  3. Elena Cassella
  4. Fabian Schmidt
  5. Jessie R Willen
  6. Dennis Voronin
  7. Trinity M Zang
  8. Theodora Hatziioannou
  9. Paul D Bieniasz
(2019)
Rhabdo-immunodeficiency virus, a murine model of acute HIV-1 infection
eLife 8:e49875.
https://doi.org/10.7554/eLife.49875

Share this article

https://doi.org/10.7554/eLife.49875

Further reading

    1. Microbiology and Infectious Disease
    Louise Tzung-Harn Hsieh, Belinda S Hall ... Rachel E Simmonds
    Research Article

    The drivers of tissue necrosis in Mycobacterium ulcerans infection (Buruli ulcer disease) have historically been ascribed solely to the directly cytotoxic action of the diffusible exotoxin, mycolactone. However, its role in the clinically evident vascular component of disease aetiology remains poorly explained. We have now dissected mycolactone’s effects on human primary vascular endothelial cells in vitro. We show that mycolactone-induced changes in endothelial morphology, adhesion, migration, and permeability are dependent on its action at the Sec61 translocon. Unbiased quantitative proteomics identified a profound effect on proteoglycans, driven by rapid loss of type II transmembrane proteins of the Golgi, including enzymes required for glycosaminoglycan (GAG) synthesis, combined with a reduction in the core proteins themselves. Loss of the glycocalyx is likely to be of particular mechanistic importance, since knockdown of galactosyltransferase II (beta-1,3-galactotransferase 6; B3GALT6), the GAG linker-building enzyme, phenocopied the permeability and phenotypic changes induced by mycolactone. Additionally, mycolactone depleted many secreted basement membrane components and microvascular basement membranes were disrupted in vivo during M. ulcerans infection in the mouse model. Remarkably, exogenous addition of laminin-511 reduced endothelial cell rounding, restored cell attachment and reversed the defective migration caused by mycolactone. Hence supplementing mycolactone-depleted extracellular matrix may be a future therapeutic avenue, to improve wound healing rates.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Ana Patrícia Graça, Vadim Nikitushkin ... Gerald Lackner
    Research Article

    Mycofactocin is a redox cofactor essential for the alcohol metabolism of mycobacteria. While the biosynthesis of mycofactocin is well established, the gene mftG, which encodes an oxidoreductase of the glucose-methanol-choline superfamily, remained functionally uncharacterized. Here, we show that MftG enzymes are almost exclusively found in genomes containing mycofactocin biosynthetic genes and are present in 75% of organisms harboring these genes. Gene deletion experiments in Mycolicibacterium smegmatis demonstrated a growth defect of the ∆mftG mutant on ethanol as a carbon source, accompanied by an arrest of cell division reminiscent of mild starvation. Investigation of carbon and cofactor metabolism implied a defect in mycofactocin reoxidation. Cell-free enzyme assays and respirometry using isolated cell membranes indicated that MftG acts as a mycofactocin dehydrogenase shuttling electrons toward the respiratory chain. Transcriptomics studies also indicated remodeling of redox metabolism to compensate for a shortage of redox equivalents. In conclusion, this work closes an important knowledge gap concerning the mycofactocin system and adds a new pathway to the intricate web of redox reactions governing the metabolism of mycobacteria.